Revenio Oyj : Group Corporation - New member appointed to 's Management Team

Stock Exchange Release December 19, 2019, at 11.00

NEW MEMBER APPOINTED TO REVENIO'S MANAGEMENT TEAM

Revenio Group Corporation has appointed Giuliano Barbaro, M.Sc.Eng. to its Management Team. Barbaro, who has worked as the Head of Ocular Imaging Device R&D at CenterVue S.p.A. since 2008, will join the Management Team on 1 January 2020.

"With the acquisition of CenterVue, it is important that we strengthen our Management Team with Giuliano's expertise and knowhow in CenterVue's imaging devices. Giuliano has years of experience in research and development of ocular diagnostic equipment, and he will offer valuable insight into how we can develop our diagnostic device business. I am very pleased to welcome Giuliano to the Management Team of Revenio Group Corporation", Revenio Group CEO Timo Hildén says.

The Management Team of Revenio Group includes Revenio Group Corporation's CEO Timo Hildén (chair), Revenio Group Corporation's CFO Robin Pulkkinen, Sales and Marketing Director Tomi Karvo, R&D Director Mika Salkola, Operations Director Ari Isomäki, QA Manager Heli Huopaniemi and R&D Director of Imaging Devices Giuliano Barbaro.

Revenio Group Corporation

CEO Timo Hildén, tel. [phone]

[e-mail]

www.revenio.fi

DISTRIBUTION:

Nasdaq Helsinki Oy

Financial Supervisory Authority (FIN-FSA)

Principal media

www.revenio.fi

The Revenio Group in brief

Operating on the international market, Revenio is a health technology group and a global leader in ophthalmic diagnostic solutions.

 

The common denominators of Revenio's business operations include patient-led screening, follow-up and the global need to make cost savings in health care via preventive measures. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The goal is to create better quality of life through health technology solutions that enable more efficient diagnostics. The focus of the Group is on the early detection of glaucoma, diabetic retinopathy, and macular degeneration, and the monitoring of these during the treatment process. Revenio's Research function focuses on the commercialization of systems that support the diagnosis of skin cancer and asthma and planning their treatment.

The Revenio Group comprises Icare Finland Oy, Icare USA Inc., Revenio Italy S. R. L, CenterVue SpA, CenterVue Inc., Revenio Research Oy, and Oscare Medical Oy.

 

In 2018, the Group's net sales totaled EUR 30.7 million, with its operating margin standing at 33.3%. Revenio Group Corporation is listed on Nasdaq Helsinki.

https://news.cision.com/revenio-group-oyj/r/revenio-group-corporation---new-member-appointed-to-revenio-s-management-team,c2995263

(c) 2019 Cision. All rights reserved., source Press Releases - English